Brain scan study aims to spot Alzheimer's years early
NCT ID NCT05138263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 640 adults with normal cognition, mild cognitive impairment, or Alzheimer's disease to track brain changes over time. Researchers use advanced brain scans and genetic tests to understand how Alzheimer's develops. The goal is to find better ways to diagnose and predict the disease early.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors detect Alzheimer's earlier and predict who might develop it, leading to better planning and care.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may take years to apply in practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 640 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Young and elderly normal controls: community-based population AD and MCI: clinic or community-based population
- Ages
-
20 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Participants will be classified as either Alzheimer's disease(AD) group, mild cognitive impairment(MCI) group, elderly normal controls or young normal controls. Specific inclusion criteria for each group is described below. Inclusion Criteria: \[Inclusion criteria: AD\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 or 1 * Diagnostic and Statistical Manual-IV(DSM-IV) criteria for dementia * National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia * Study partner or caregiver to accompany patient to all scheduled visits * Written informed consent \[Inclusion criteria: MCI (amnestic)\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0.5 * Concern regarding a change in cognition (obtained from the subject, from an informant who knows the subject, or from a skilled clinician observing the subject) * Lower performance in any cognitive domain that is greater than would be expected for the subject's age and educational background * Preservation of independence in functional abilities * Study partner or caregiver to accompany subject to all scheduled visits * Written informed consent \[Inclusion criteria: Elderly normal controls\] * Age : 55 - 90 * Clinical Dementia Rating (CDR)=0 * Those with contactable Informant * Written informed consent \[Inclusion criteria: Young normal controls\] * Age : 20 - 54 * Clinical Dementia Rating (CDR)=0 * Written informed consent Exclusion Criteria: \[Exclusion criteria: general\] * Past history or presence of major psychiatric illness (e.g. schizophrenia, bipolar disorder, alcohol/substance abuse or dependence, delirium) * Significant neurologic or medical condition that can influence the mental state * Contraindications for MRI scan (e.g. pacemaker, claustrophobia) * Illiteracy * Significant visual or hearing difficulty * Taking investigational drug * In pregnancy or breast-feeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SMG-SNU Boramae Medical Center
Seoul, Seoul, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Walking memory tests may reveal early Parkinson's clues
- Can tango rewire the brain? dance program tested for Parkinson's and dementia